therapy drug called immune checkpoint inhibitors can recognize and attack cancer cells
exhibiting better outcomes for other cancer types and also studies have showed it is also
effective for osteosarcoma treatment. Moreover, engineered monoclonal antibodies are used to
stop cancer growth by hampering new blood vessel formation or to inhibit tumor cells by
targeting mTOR protein. For instance, Aadi, LLC studies Nivolumab (Opdivo) in combination
with ABI-009 (Nab-rapamycin, the mTOR inhibitor) for potential anti-tumor activity for Ewing
Sarcoma. The study is in phase II clinical trial, which is expected to complete by 2020.
In case of pediatric osteosarcoma, around 35% of patient fail first-line of therapy, leading to
recurrence in metastatic osteosarcoma in lungs. Therefore, development of novel drugs for
treatment of lung cancer, due to metastatic osteosarcoma will also contribute to growth of the
metastatic osteosarcoma treatment market. For instance, in 2013, Elesion Pharmaceuticals LLC,
a pharmaceutical company developing life-saving therapeutics for rare cancers, entered into
phase II clinical trials for Inhaled Lipid-complexed Cisplatin (ILC), a novel sustained release
formulation of cisplatin in a nanoscale lipid based complex, for pediatric patients with
osteosarcoma metastases for lungs. Additionally, inorganic marketing strategies adopted by
metastatic osteosarcoma drug market players is expected to aid in the market growth. For
instance, in the same year, Inhaled Lipid-complexed Cisplatin orphan drug designation by
European Medicines Agency for the treatment of osteosarcoma. Furthermore, in 2015, company
entered in partnership with Intelgen Limited, a Hong Kong-based biopharmaceutical company,
for specialized novel anti-cancer drug development and commercializing ILC in Chinese market.
Moreover, in 2014, Oncolytics Biotech, examined safety and efficacy of Reolysin for the
treatment of bone and soft tissue sarcoma metastatic for lungs.
Report includes chapters which deeply display the following deliverable about industry :
• Metastatic Osteosarcoma Treatment Market Research Objective and Assumption
• Metastatic Osteosarcoma Treatment Market Purview - Report Description, Executive Summary,
and Coherent Opportunity Map (COM)
• Metastatic Osteosarcoma Treatment Market Dynamics, Regulations, and Trends Analysis -
Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Metastatic Osteosarcoma Treatment Market, By Regions
• Metastatic Osteosarcoma Treatment Market Competition by Manufacturers including
Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and
Product Type.
• Metastatic Osteosarcoma Treatment Market Manufacturers Profiles/Analysis including Company
Basic Information, Manufacturing Base and Its Competitors.